Personalized medicine: Pharmacogenetics in psychiatry

Current Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2008, Pages 1-11

  Hinrichs, John W J ^a,b   van der Weide, Jan ^a,b  

^a ST JANSDAL HOSPITAL   (Netherlands)

^b Psychiatric Hospital Meerkanten   (Netherlands)

Author keywords

Antidepressant; Antipsychotic; Cytochrome P450; Dopamine; Dose adjustment; Polymorphism; Serotonin

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MOTOR DYSFUNCTION; PHARMACODYNAMICS; PHARMACOGENETICS; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 67649378859     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569208784017548     Document Type: Review

References (143)

1. Aklillu, E.; Persson, I.; Bertilsson, L.; Johansson, I.; Rodrigues, F. and Ingelman-Sundberg, M. (1996) Frequent Distribution of Ultrarapid Metabolizers of Debrisoquine in an Ethiopian Population Carrying Duplicated and Multduplicated Functional CYP2D6 Alleles. J. Pharmacol. Exp. Ther. 278, 441-446.
2. Albers, L. J. and Özdemir, V. (2004) Pharmacogenomic-Guided Rational Therapeutic Drug Monitoring: Conceptual Framework and Application Platforms for Atypical Antipsychotics. Curr. Med. Chem. 11, 297-312.
3. Albers, L. J.; Özdemir, V.; Marder, S. R.; Raggi, M. A.; Aravagiri, M.; Endrenyi, L. and Reist, C. (2005) Low-Dose Fluvoxamine As an Adjunct to Reduce Olanzapine Therapeutic Dose Requirements: a Prospective Dose-Adjusted Drug Interaction Study. J. Clin. Psychopharmacol. 25, 170-174.
4. Allison, D. B.; Mentore, J. L.; Heo, M.; Chandler, L. P.; Cappelleri, J. C.; Infante, M. C and Weiden, P. J. (1999) Antipsychotic-Induced Weight Gain: a Comprehensive Research Synthesis. Am. J. Psychiatry 156, 1686-1696.
5. Anderson, I. M. (2000) Selective Serotonin Reuptake Inhibitors Versus Tricyclic Antidepressants: a Meta-Analysis of Efficacy and Tolerability. J. Affect. Disord. 58, 19-36.
6. Arranz, M. J.; Collier, D.; Sodhi, M.; Ball, D.; Roberts, G.; Price, J. and Kerwin, R. (1995) Association Between Clozapine Response and Allelic Variation in 5-HT2A Receptor Gene. Lancet 346, 281-282.
7. Arranz, M. J.; Munro, J.; Birkett, J.; Bolonna, A.; Mancama, D.; Sodhi, M.; Lesch, K. P.; Meyer, J. F. W.; Sham, P.; Collier, D. A.; Murray, R. M. and Kerwin, R. W. (2000a) Pharmacogenetic Prediction of Clozapine Response. Lancet 355, 1615-1616.
8. Arranz, M. J.; Munro, J.; Osborne, S.; Collier, D. and Kerwin, R. W. (2000b) Difficulties in Replication of Results. Lancet 356, 1359-1360.
9. Arranz, M. J.; Munro, J.; Sham, P.; Kirov, G.; Murray, R. M.; Collier, D. A. and Kerwin, R. W. (1998) Meta-Analysis of Studies on Genetic Variation in 5-HT2A Receptors and Clozapine Response. Schizophr. Res. 32, 93-99.
10. Bakker, P. R.; van Harten, P. N. and van Os, J. (2006) Antipsychotic-Induced Tardive Dyskinesia and the Ser9Gly Polymorphism in the DRD3 Gene: a Meta Analysis. Schizophr. Res. 83, 185-192.
11. Belpaire, F. M.; Wijnant, P.; Temmerman, A.; Rasmussen, B. B. and Brosen, K. (1998) The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors. Eur. J. Clin. Pharmacol. 54, 261-264.
12. Bertelsen, K. M.; Venkatakrishnan, K.; von Moltke, L. L.; Obach, R. S. and Greenblatt, D. J. (2003) Apparent Mechanism-Based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison With Fluoxetine and Quinidine. Drug Metab. Dispos. 31, 289-293.
13. Bertilsson, L.; Dahl, M. L. and Tybring, G. (1997) Pharmacogenetics of Antidepressants: Clinical Aspects. Acta. Psychiatr. Scand. Suppl. 391, 14-21.
14. Bertilsson, L.; Lou, Y. Q.; Du, Y. L.; Liu, Y.; Kuang, T. Y.; Liao, X. M.; Wang, K. Y.; Reviriego, J.; Iselius, L. and Sjoqvist, F. (1992) Pronounced Differences Between Native Chinese and Swedish Populations in the Polymorphic Hydroxylations of Debrisoquine and S-Mephenytoin. Clin. Pharmacol. Ther. 51, 388-397.
15. Broly, F. and Meyer, U. A. (1993) Debrisoquine Oxidation Polymorphism: Phenotypic Consequences of a 3-Basepair Deletion in Exon 5 of the CYP2D6 Gene. Pharmacogenetics 3, 123-130.
16. Buckland, P. R.; Hoogendoorn, B.; Guy, C. A.; Smith, S. K.; Coleman, S. L. and O'Donavan, M. C. (2005) Low Gene Expression Conferred by Association of an Allele of the 5-HT2C Receptor Gene With Antipsychotic-Induced Weight Gain. Am. J. Psychiatry 162, 613-615.
17. Burke, M. J. and Preskorn, S. H. (1999) Therapeutic Drug Monitoring of Antidepressants: Cost Implications and Relevance to Clinical Practice. Clin. Pharmacokinet. 37, 147-165.
18. Carrillo, J. A. and Benitez, J. (2000) Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications. Clin. Pharmacokinet. 39, 127-153.
19. Carrillo, J. A.; Herraiz, A. G.; Ramos, S. I.; Gervasini, G.; Vizcaino, S and Benitez, J. (2003) Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine. J. Clin. Psychopharmacol. 23, 119-127.
20. Dahan, A. and Altman, H. (2004) Food-Drug Interaction: Grapefruit Juice Augments Drug Bioavailability - Mechanism, Extent and Relevance. Eur. J. Clin. Nutr. 58, 1-9.
21. Dahl, M. L. (2002) Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics. Clin. Pharmacokinet. 41, 453-470.
22. Dahl, M. L.; Johansson, I.; Bertilsson, L.; Ingelman-Sundberg, M. and Sjöqvist, F. (1995) Ultrarapid Hydroxylation of Debrisoquine in a Swedish Population. Analysis of the Molecular Genetic Basis. J. Pharmacol. Exp. Ther. 274, 516-520.
23. Davies, M. A.; Setola, V.; Strachan, R. T.; Sheffler, D. J.; Salay, E.; Hufeisen, S. J. and Roth, B. L. (2006) Pharmacologic Analysis of Non-Synonymous Coding H5-HT2A SNPs Reveals Alterations in Atypical Antipsychotic and Agonist Efficacies. Pharmacogenomics J. 6, 42-51.
24. de Leon, J.; Susce, M. T. and Murray-Carmichael, E. (2006) The AmpliChip CYP450 Genotyping Test: Integrating a New Clinical Tool. Mol. Diagn. Ther. 10, 135-151.
25. de Leon, J.; Susce, M. T.; Pan, R. M.; Fairchild, M.; Koch, W. H. and Wedlund, P. J. (2005) The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperdone Adverse Drug Reactions and Discontinuation. J. Clin. Psychiatry 66, 15-27.
26. De Luca, V.; Mueller, D. J.; De Bartolomeis, A. and Kennedy, J. L. (2007) Association of the HTR2C Gene and Antipsychotic Induced Weight Gain: a Meta-Analysis. Int. J. Neuropsychopharmacol.
27. De Morais, S. M. F.; Wilkinson, G. R.; Blaisdell, J.; Meyer, U. A.; Nakamura, K. and Goldstein, J. A. (1994a) Identification of a New Genetic Defect Responsible for the Polymorphism of (S)-Mephenytoin Metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
28. De Morais, S. M. F.; Wilkinson, G. R.; Blaisdell, J.; Nakamura, K.; Meyer, U. A. and Goldstein, J. A. (1994b) The Major Genetic Defect Responsible for the Polymorphism of S-Mephenytoin Metabolism in Humans. J. Biol. Chem. 269, 15419-15422.
29. Degner, D.; Grohmann, R.; Kropp, S.; Ruther, E.; Bender, S.; Engel, R. R. and Schmidt, L. G. (2004) Severe Adverse Drug Reactions of Antidepressants: Results of the German Multicenter Drug Surveillance Program AMSP. Pharmacopsychiatry 37, S39-45.
30. Desta, Z.; Zhao, X.; Shin, J. G. and Flockhart, D. A. (2002) Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clin. Pharmacokinet. 41, 913-958.
31. Duggan, M. (2005) Do New Prescription Drugs Pay for Themselves? Th Case of Second-Generation Antipsychotics. J. Health Econ. 24, 1-31.
32. Eap, C. B.; Sirot, E. J. and Baumann, P. (2004) Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies. Ther. Drug Monit. 26, 152-155.
33. Eichelbaum, M.; Spannbrucker, N.; Steinke, B. and Dengler, H. J. (1979) Defective N-Oxidation of Sparteine in Man: a New Pharmacogenetic Defect. Eur. J. Clin. Pharmacol. 16, 183-187.
34. Ellingrod, V. L.; Bishop, J. R.; Moline, J.; Lin, Y. C. and Miller, D. (2007) Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) From Olanzapine Treatment in Persons With Schizophrenia. Psychopharmacol. Bull. 40, 57-62.
35. Ellingrod, V. L.; Perry, P. J.; Lund, B. C.; Bever-Stille, K.; Fleming, F.; Holman, T. L. and Miller, D. (2002) 5HT2A and 5HT2C Receptor Polymorphisms and Predicting Clinical Response to Olanzapine in Schizophrenia. J. Clin. Psychopharmacol. 22, 622-624.
36. Franssen, E. J. F.; Meijs, V.; Ettaher, F.; Valerio, P. G.; Keessen, M. and Lameijer, W. (2006) Citalopram Serum and Milk Levels in Mother and Infant During Lactation. Ther. Drug Monit. 28, 2-4.
37. Gaedigk, A.; Blum, M.; Gaedigk, R.; Eichelbaum, M. and Meyer, U. A. (1991) Deletion of the Entire Cytochrome P450 CYP2D6 Gene As a Cause of Impaired Drug Metabolism in Poor Metabolizers of the Debrisoquine/ Sparteine Polymorphism. Am. J. Hum. Genet. 48, 943-950.
38. Gaedigk, A.; Ryder, D. L.; Bradford, L. D. and Leeder, J. S. (2003) CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the -1584G Promotor Polymorphism. Clin. Chem. 49, 1008-1011.
39. Gardiner, S. J. and Begg, E. J. (2005) Pharmacogenetic Testing for Drug Metabolizing Enzymes: Is It Happening in Practice? Pharmacogenetics 15, 365-369.
40. Glue, P. and Banfield, C. (1996) Psychiatry, Psychopharmacology and P450s. Hum. Psychopharmacol. 11, 97-114.
41. Gough, A. C.; Miles, J. S.; Spurr, N. K.; Moss, J. E.; Gaedigk, A.; Eichelbaum, M. and Wolf, C. R. (1990) Identification of the Primary Gene Defect at the Cytochrome P450 CYP2D Locus. Nature 347, 773-776.
42. Grasmader, K.; Verwohlt, P. L.; Rietschel. M.; Dragicevic, A.; Muller, M.; Hiemke, C.; Freymann, N.; Zobel, A.; Maier, W. and Rao, M. L. (2004) Impact of Polymorphisms of Cytochrome-P450 Isoenzymes 2C9, 2C19 and 2D6 on Plasma Concentrations and Clinical Effects of Antidepressants in a Naturalistic Clinical Setting. Eur. J. Clin. Pharmacol. 60, 329-336.
43. Greenberg, B. D.; Tolliver, T. J.; Huang, S. J.; Li, Q.; Bengel, D. and Murphy, D. L. (1999) Genetic Variation in the Serotonin Transporter Promotor Region Affects Serotonin Uptake in Human Blood. Am. J. Med. Genet. 88, 83-87.
44. Han, X. M.; Ou-Yang, D. S.; Lu, P. X.; Jiang, C. H.; Shu, Y.; Chen, X. P.; Tan, Z. R. and Zhou, H. H. (2001) Plasma Caffeine Metabolite Ratio (17X/137X) in Vivo Associated With G-2964A and C734A Polymorphisms of Human CYP1A2. Pharmacogenetics 11, 429-435.
45. Hedgecoe, A. (2007) Education, Ethics and Knowledge Deficits in Clinical Pharmacogenetics. Pharmacogenomics 8, 267-270.
46. Heils, A.; Teufel, A.; Petri, S.; Stober, G.; Riederer, P.; Bengel, D. and Lesch, K. P. (1996) Allelic Variation of Human Serotonin Transporter Gene Expression. J. Neurochem. 66, 2621-2624.
47. Heller, T.; Kirchheiner, J.; Armstrong, V. W.; Luthe, H.; Tzvetkov, M.; Brockmoller, J. and Oellerich, M. (2006) AmpliChip CYP450 GeneChip: a New Gene Chip That Allows Rapid and Accurate CYP2D6 Genotyping. Ther. Drug Monit. 28, 673-677.
48. Hersberger, M.; Marti-Jaun, J.; Rentsch, K. and Hanseler, E. (2000) Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR. Clin. Chem. 46, 1072-1077.
49. Hersberger, M.; Marti-Jaun, J.; Rentsch, K. and Hanseler, E. (2001) Two Single-Tube Tetra-Primer Assays to Detect the CYP2C19*2 and *3 Alleles of S-Mephenytoin Hydroxylase. Clin. Chem. 47, 772-774.
50. Hiemke, C. and Hartter, S. (2000) Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Pharmacol. Ther. 85, 11-28.
51. Hiemke, C.; Peled, A.; Jabarin, M.; Hadjez, J.; Weigmann, H.; Hartter, S.; Modai, I.; Ritsner, M. and Silver, H (2002) Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects. J. Clin. Psychopharmacol. 22, 502-506.
52. Hinrichs, J. W. J.; Smallegoor, W. D.; van Baalen-Benedek, E. H.; Welker, C. and van der Weide, J. (2007) Detection of CYP2D6 Polymorphisms *9, *10, and *41 Using ARMS-PCR and Their Allelic Frequencies Among 400 Psychiatric Patients. Clin. Chem. Lab. Med. 45, 555-557.
53. Ingelman-Sundberg, M. (2005) Genetic Polymorphisms of Cytochrome P450 2D6 (CYP2D6): Clinical Consequences, Evolutionary Aspects and Functional Diversity. The Pharmacogenomics J. 5, 6-13.
54. Ingelman-Sundberg, M. (2004) Pharmacogenetics of Cytochrome P450 and Its Application in Drug Therapy: the Past, Present and Future. Trends Pharmacol. Sci. 25, 193-200.
55. Ingelman-Sundberg, M.; Oscarson, M. and McLellan, R. A. (1999) Polymorphic Human Cytochrome P450 Enzymes: an Opportunity for Individualized Drug Treatment. Trends Pharmacol. Sci. 20, 342-349.
56. Jerling, M.; Lindström, L.; Bondesson, U. and Bertilsson, L. (1994) Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence From a Therapeutic Drug Monitoring Service. Ther. Drug Monit. 16, 368-374.
57. Johansson, I.; Lundqvist, E.; Bertilsson, L.; Dahl, M. L.; Sjoqvist, F. and Ingelman-Sundberg, M. (1993) Inherited Amplification of an Active Gene in the Cytochrome P450 CYP2D Locus As a Cause of Ultrarapid Metabolism of Debrisoquine. Acad. Sci. USA 90, 11825-11829.
58. Johansson, I.; Oscarson, M.; Yue, Q. Y.; Bertilsson, L.; Sjoqvist, F. and Ingelman-Sundberg, M. (1994) Genetic Analysis of the Chinese Cytochrome P4502D Locus: Characterization of Variant CYP2D6 Genes Present in Subjects With Diminished Capacity for Debrisoquine Hydroxylation. Mol. Pharmacol. 46, 452-459.
59. Jones, P. B.; Barnes, T. R. E.; Davies, L.; Dunn, G.; Lloyd, H.; Hayhurst, K. P.; Murray, R. M.; Markwick, A. and Lewis, S. W. (2006) Randomized Controlled Trial of the Effect on Quality of Life of Second- Vs First-Generation Antipsychotic Drugs in Schizophrenia. Arch. Gen. Psychiatry 63, 1079-1087.
60. Kagimoto, M.; Heim, M.; Kagimoto, K.; Zeugin, T. and Meyer, U. A. (1990) Multiple Mutations of the Human Cytochrome P450IID6 Gene (CYP2D6) in Poor Metabolizers of Debrisoquine. Study of the Functional Significance of Individual Mutations by Expression of Chimeric Genes. J. Biol. Chem. 265, 17209-17214.
61. Kapur, S. and Seeman, P. (2001) Does Fast Dissociation From the Dopamine D(2) Receptor Explain the Action of Atypical Antipsychotics?: a New Hypothesis. Am. J. Psychiatry 158, 360-369.
62. Kim, D. K.; Lim, S. W.; Sohn, S. E.; Kim, S.; Hahn, C. G. and Carroll, B. J. (2000) Serotonin Transporter Gene Polymorphism and Antidepressant Response. Neuroreport 11, 215-219.
63. Kirchheiner, J. and Brockmöller, J. (2005) Clinical Consequences of Cytochrome P450 2C9 Polymorphisms. Clin. Pharmacol. Ther. 77, 1-16.
64. Kirchheiner, J.; Brøsen, K.; Dahl, M. L.; Gram, L. F.; Kasper, S.; Roots, I.; Sjöqvist, F.; Spina, E. and Brockmöller, J. (2001) CYP2D6 and CYP2C19 Genotype-Based Dose Recommendations for Antidepressants: a First Step Towards Subpopulation-Specific Dosages. Acta. Psychiatr. Scand. 104, 173-192.
65. Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M. L.; Licinio, J.; Roots, I. and Brockmöller, J. (2004) Pharmacogenetics of Antidepressants and Antipsychotics: the Contribution of Allelic Variations to the Phenotype of Drug Response. Mol. Psychiatry 9, 442-473.
66. Kirchheiner, J.; Nickchen, K.; Sasse, J.; Bauer, M.; Roots, I. and Brockmoller, J. (2006) A 40-Basepair VNTR Polymorphism in the Dopamine Transporter (DAT1) Gene and the Rapid Response to Antidepressant Treatment. Pharmacogenomics J. 7, 48-55.
67. Knoppert, D. C.; Nimkar, R.; Principi, T. and Yuen, D. (2006) Paroxetine Toxicity in a Newborn After in Utero Exposure. Ther. Drug Monit. 28, 5-7.
68. Konig, F.; Hafele, M.; Hauger, B.; Loble, M.; Wossner, S. and Wolfersdorf, M. (1996) Bradycardia After Beginning Therapy With Metoprolol and Paroxetine. Psychiatr Prax 23, 244-245.
69. Kootstra-Ros, J. E.; Smallegoor, W. D. and van der Weide, J. (2005) The Cytochrome P450 CYP1A2 Genetic Polymorphisms *1F and *1D Do Not Affect Clozapine Clearance in a Group of Schizophrenic Patients. Ann. Clin. Biochem. 42, 216-219.
70. Kootstra-Ros, J. E.; van Weelden, M. J. M.; Hinrichs, J. W. J.; De Smet, P. A. and van der Weide, J. (2006) Therapeutic Drug Monitoring of Antidepressants and Cytochrome P450 Genotyping in General Practice. J. Clin. Pharmacol. 46, 1320-1327.
71. Kraft, J. B.; Peters, E. J.; Slager, S. L.; Jenkins, G. D.; Reinalda, M. S.; McGrath, P. J. and Hamilton, S. P. (2006) Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample. Biol. Psychiatry 61, 734-742.
72. Kropp, S.; Lichtinghagen, R.; Winterstein, K.; Schlimme, J. and Schneider, U. (2006) Cytochrome P-450 2D6 and 2C19 Polymorphisms and the Length of Hospitalization in Psychiatry. Clin. Lab. 52, 237-240.
73. Lane, H. Y.; Chang, Y. C.; Chiu, C. C.; Chen, M. L.; Hsieh, M. H. and Chang, W. H. (2002) Association of Risperidone Treatment Response With a Polymorphism in the 5-HT(2A) Receptor Gene. Am. J. Psychiatry 159, 1593-1595.
74. Lane, H. Y.; Liu, Y. C.; Huang, C. L.; Chang, Y. C.; Wu, P. L.; Lu, C. T. and Chang, W. H. (2006) Risperidone-Related Weight Gain. Genetic and Nongenetic Predictors. J. Clin. Psychopharmacol. 26, 128-134.
75. Lencz, T.; Robinson, D. G.; Xu, K.; Ekholm, J.; Sevy, S.; Gunduz-Bruce, H.; Woerner, M. G.; Kane, J. M.; Goldman, D. and Malhotra, A. K. (2006) DRD2 Promotor Region Variation As a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients. Am. J. Psychiatry 163, 529-531.
76. Lerer, B.; Segman, R.; Fangerau, H.; Daly, A. K.; Basile, V. S.; Cavallaro, R.; Aschauer, H. N.; McCreadie, R. G.; Ohlraun, S.; Ferrier, N.; Masellis, M.; Verga, M.; Scharfetter, J.; Rietschel, M.; Lovlie, R.; Levy, U. H.; Meltzer, H. Y.; Kennedy, J. L.; Steen, V. M. and Macciardi, F. (2002) Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association With Dopamine D3 Receptor Gene Ser9Gly Polymorphism. Neuropsychopharmacology 27, 105-119.
77. Lerer, B.; Segman, R. H.; Tan, E. C.; Basile, V. S.; Cavallaro, R.; Aschauer, H. N.; Strous, R.; Chong, S. A.; Heresco-Levy, U.; Verga, M.; Scharfetter, J.; Meltzer, H. Y.; Kennedy, J. L. and Macciardi, F. (2005) Combined Analysis of 635 Patients Confirms an Age-Related Association of the Serotonin 2A Receptor Gene With Tardive Dyskinesia and Specificity for the Non-Orfacial Subtype. Int. J. Neuropsychopharmacol. 8, 411-425.
78. Mahgoub, A.; Idle, J. R.; Dring. D. G.; Lancaster, R. and Smith, R. L. (1977) Polymorphic Hydroxylation of Debrisoquine in Man. Lancet 2, 584-586.
79. Masimirembwa, C.; Persson, I.; Bertilsson, L.; Hasler, J. and Ingelman-Sundberg, M. (1996) A Novel Mutant Variant of the CYP2D6 Gene (CYP2D6*17) Common in a Black African Population: Association With Diminished Debrisoquine Hydroxylase Activity. Br. J. Clin. Pharmacol. 42, 713-719.
80. Melkersson, K. I.; Scordo, M. G.; Gunes, A. and Dahl, M. L. (2007) Impact of CYP1A2 and CYP2D6 Polymorphisms on Drug Metabolism and on Insulin and Lipid Elevations and Insulin Resistance in Clozapine-Treated Patients. J. Clin. Psychiatry 68, 697-704.
81. Miller, D. D.; Ellingrod, V. L.; Holman, T. L.; Buckley, P. F. and Arndt, S. (2005) Clozapine-Induced Weight Gain Associated With the 5HT2C Receptor -759C/T Polymorphism. Am. J. Med. Genet. 133, 97-100.
82. Miyamoto, S.; Duncan, G. E.; Marx, C. E and Lieberman. J. A. (2005) Treatments for Schizophrenia: a Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs. Mol. Psychiatry 10, 79-104.
83. Mulder, H.; Franke, B.; Aart van der-Beek van der, A.; Arends, J.; Wilmink, F. W.; Egberts, A. C. and Scheffer, H. (2007) The Association Between HTR2C Polymorphisms and Obesity in Psychiatric Patients Using Antipsychotics: a Cross-Sectional Study. Pharmacogenomics J. 7(5), 318-324.
84. Mulder, H.; Wilmink, F. W.; Beumer, T. L.; Tamminga, W. J.; Jedema, J. N. and Egberts, A. C. G. (2005) The Association Between Cytochrome P450 2D6 Genotype and Prescription Patterns of Antipsychotic and Antidepressant Drugs in Hospitalized Psychiatric Patients. J. Clin. Psychopharmacol. 25, 188-191.
85. Muller, M. J.; Dragicevic, A.; Fric, M.; Gaertner, I.; Grasmader, K.; Hartter, S.; Hermann, E.; Kuss, H. J.; Laux, G.; Oehl,, W.; Rao M. L.; Rollmann, N.; Weigmann, H.; Weber-Labonte, M. and Hiemke, C. (2003) Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does It Work Under Clinical Conditions? Pharmacopsychiatry 36, 98-104.
86. Nakajima, M.; Yokoi, T.; Mizutani, M.; Kinoshita, M.; Funayama, M. and Kamataki, T. (1999) Genetic Polymorphism in the 5′-Flanking Region of Human CYP1A2 Gene: Effect on the CYP1A2 Inducibility in Humans. J. Biochem. (Tokyo) 125, 803-808.
87. Nebert, D. W. (1997) Polymorphisms in Drug-Metabolizing Enzymes: What Is Their Clinical Relevance and Why Do They Excist? Am. J. Hum. Genet. 60, 265-271.
88. Neville, M. J.; Johnstone, E. C. and Walton, R. T. (2004) Identification and Characterization of ANKK1: a Novel Kinase Gene Closely Linked to DRD2 on Chromosome Band 11q23.1. Hum. Mutat. 23, 540-545.
89. Özdemir, V.; Gunes, A.; Dahl, M. L.; Scordo, M. G.; Williams-Jones, B. and Someya, T. (2006) Could Endogenous Substrates of Drug-Metabolizing Enzymes Influence Constitutive Physiology and Drug Target Responsiveness? Pharmacogenomics 7, 1199-1210.
90. Özdemir, V.; Kalow, W.; Tothfalusi, L.; Bertilsson, L.; Endrenyi, L. and Graham, J. E. (2005) Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: the Need for an Upper-Bound Estimate of Genetic Contributions. Curr. Pharmacogenomics 3, 53-71.
91. Park, Y. M.; Chung, Y. C.; Lee, S. H.; Lee, K. J.; Kim, H.; Byun, Y. C.; Lim, S. W.; Paik, J. W. and Lee, H. J. (2006) Weight Gain Associated With the Alpha2a-Adrenergic Receptor -1291 C/G Polymorphism and Olanzapine Treatment. Am. J. Med. Genet. 141B, 394-397.
92. Pollock, B. G.; Ferrell, R. E.; Mulsant, B. H.; Mazumdar, S.; Miller, M.; Sweet, R. A.; Davis, S.; Kirshner, M. A.; Houck, P. R.; Stack, J. A.; Reynolds, C. F. and Kupfer, D. J. (2000) Allelic Variation in the Serotonin Transporter Promotor Affects Onset of Paroxetine Treatment Response in Late-Life Depression. Neuropsychopharmacology 23, 587-590.
93. Prior, T. I. and Baker, G. B. (2007) Interactions Between the Cytochrome P450 System and the Second-Generation Antipsychotics. J. Psychiatry Neurosci. 28, 99-112.
94. Raaska, K. and Neuvonen, P. J. (2000) Ciprofloxacin Increases Serum Clozapine and N-Desmethylclozapine: a Study in Patients With Schizophrenia. Eur. J. Clin. Pharmacol. 56, 585-589.
95. Raaska, K.; Raitasuo, V.; Laitila, J. and Neuvonen, P. J. (2004) Effect of Caffeine-Containing Versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients. Pharmacol. Toxicol. 94, 13-18.
96. Raimundo, S.; Fischer, J.; Eichelbaum, M.; Griese, E. U.; Schwab, M. and Zanger, U. M. (2000) Elucidation of the Genetic Basis of the Common 'Intermediate Metabolizer' Phenotype for Drug Oxidation by CYP2D6. Pharmacogenetics 10, 577-581.
97. Raimundo, S.; Toscano, C.; Klein, K.; Fischer, J.; Griese, E. U.; Eichelbaum, M.; Schwab, M. and Zanger, U. M. (2004) A Novel Intronic Mutation, 2988G>A, With High Predictivity for Impaired Function of Cytochrome P450 2D6 in White Subjects. Clin. Pharmacol. Ther. 76, 128-138.
98. Rettie, A. E.; Wienkers, L. C.; Gonzalez, F. J.; Trager, W. F. and Korekwa, K. R. (1994) Impaired (S)-Warfarin Metabolism Catalysed by the R144C Allelic Variant of CYP2C9. Pharmacogenetics 4, 39-42.
99. Reynolds, G. P.; Zhang, Z. J. and Zhang, X. B. (2002) Association of Antipsychotic Drug-Induced Weight Gain With a 5-HT2C Receptor Gene Polymorphism. Lancet 359, 2086-2087.
100. Roberts, R. L. and Kennedy, M. A. (2006) Rapid Detection of Common Cytochrome P450 2D6 Alleles in Caucasians. Clin. Chim. Acta 366, 348-351.
101. Rodriguez-Antona, C. and Ingelman-Sundberg, M. (2006) Cytochrome P450 Pharmacogenetics and Cancer. Oncogene 25, 1679-1691.
102. Rosholm, J. U.; Gram, L. F.; Isacsson, G.; Hallas, J. and Bergman, U. (1997) Changes in the Pattern of Antidepressant Use Upon the Introduction of the New Antidepressants: a Prescription Database Study. Eur. J. Clin. Pharmacol. 52, 205-209.
103. Rostami-Hodjegan, A.; Amin, A. M.; Spencer, E. P.; Lennard, M. S.; Tucker, G. T. and Flanagan, R. J. (2004) Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: a Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients. J. Clin. Psychopharmacol. 24, 70-78.
104. Rostami-Hodjegan, A.; Ros, J. E.; van der Weide, J.; Flanagan, R. J.; Lennard, M. and Tucker, G. T. (2003) Validation of a Predictive Model for Individualizing Clozapine Dose. J. Psychopharmacol. 17, A54-A54 Suppl. S.
105. Rudberg, I.; Mohebi, B.; Hermann, M.; Refsum, H. and Molden, E. (2007) Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients. Clin. Pharmacol. Ther.
106. Sachse, C.; Brockmöller, J.; Bauer, S. and Roots, I. (1999) Functional Significance of a C-->A Polymorphism in Intron 1 of the Cytochrome P450 CYP1A2 Gene Tested With Caffeine. Br. J. Clin. Pharmacol. 47, 445-449.
107. Saxena, R.; Shaw, G. L.; Relling, M. V.; Frame, J. N.; Moir, D. T.; Evans, W. E.; Caporaso, N. and Weiffenbach, B. (1994) Identification of a New Variant CYP2D6 Allele With a Single Base Deletion in Exon 3 and Its Association With the Poor Metabolizer Type. Hum. Mol. Genet. 3, 923-926.
108. Schaeffeler, E.; Schwab, M.; Eichelbaum, M. and Zanger, U. M. (2003) CYP2D6 Genotyping Strategy Based on Gene Copy Number Determination by TaqMan Real-Time PCR. Hum. Mutat. 22, 476-485.
109. Schafer, M.; Rujescu, D.; Giegling, I.; Guntermann, A.; Erfurth, A.; Bondy, B. and Moller, H. J. (2001) Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D(2) Rceptor Gene. Am. J. Psychiatry 158, 802-804.
110. Schillevoort, I.; de Boer, A.; van der Weide, J.; Steijns, L. S. W.; Roos, R. A.; Jansen, P. A. and Leufkens, H. G. (2002) Antipsychotic-Induced Extrapyramidal Syndromes and Cytochrome P450 2D6 Genotype: a Case-Control Study. Pharmacogenetics 12, 235-240.
111. Schumacher, J.; Schulze, T. G.; Wienker, T. F.; Rietschel, M. and Nothen, M. M. (2000) Pharmacogenetics of the Clozapine Response. Lancet 356, 506-507.
112. Segman, R.; Neeman, T.; Heresco-Levy, U.; Finkel, B.; Karagichev, L.; Schlafman, M.; Dorevitch, A.; Yakir, A.; Lerner, A.; Shelevoy, A. and Lerer, B. (1999) Genotypic Association Between the Dopamine D3 Receptor and Tardive Dyskinesia in Chronic Schizophrenia. Mol. Psychiatry 4, 247-253.
113. Segman, R. H.; Heresco-Levy, U.; Finkel, B.; Goltser, T.; Shalem, R.; Schlafman, M.; Dorevitch, A.; Yakir, A.; Greenberg, D.; Lerner, A. and Lerer, B. (2001) Association Between the Serotonin 2A Receptor Gene and Tardive Dyskinesia in Chronic Schizophrenia. Mol. Psychiatry 6, 225-229.
114. Silver, H. (2003) Selective Serotonin Reuptake Inhibitor Augmentation in the Treatment of Negative Symptoms of Schizophrenia. Int. Clin. Psychopharmacol. 18, 305-313.
115. Sim, S. C.; Risinger, C.; Dahl, M. L.; Aklillu, E.; Christensen, M.; Bertilsson, L. and Ingelman-Sundberg, M. (2006) A Common Novel CYP2C19 Gene Variant Causes Ultrarapid Metabolism Relevant for the Drug Response to Proton Pump Inhibitors and Antidepressants. Clin. Pharmacol. Ther. 79, 103-113.
116. Sirey, J. A.; Meyers, B. S.; Bruce, M. L.; Alexopoulos, G. S.; Perlick, D. A. and Raue, P. (1999) Predictors of Antidepressant Prescripton and Early Use Among Depressed Outpatients. Am. J. Psychiatry 156, 690-696.
117. Sistonen, J.; Sajantila, A.; Lao, O.; Corander, J.; Barbujani, G. and Fuselli, S. (2007) CYP2D6 Worldwide Genetic Variation Shows High Frequency of Altered Activity Variants and No Continental Structure. Pharmacogenetics and Genomics 17, 93-101.
118. Smeraldi, E.; Zanardi, R.; Benedetti, F.; Di Bella, D.; Perez, J. and Catalano, M. (1998) Polymorphism Within the Promotor of the Serotonin Transporter Gene and Antidepressant Efficacy of Fluvoxamine. Mol. Psychiatry 3, 508-511.
119. Spina, E.; Avenoso, A.; Facciola, G.; Scordo, M. G.; Ancione, M. and Madia, A. (2001) PLasma Concentrations of Risperidone and 9-Hydroxyrisperidone During Combined Treatment With Paroxetine. Ther. Drug Monit. 23, 223-227.
120. Spina, E.; Avenoso, A.; Scordo, M. G.; Ancione, M.; Gatti, G. and Perucca. E. (2002) Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: a Clinically Relevant Pharmacokinetic Drug Interaction. J. Clin. Psychopharmacol. 22, 419-423.
121. Spina, E. and de Leon, J. (2007) Metabolic Drug Interactions With Newer Antipsychotics: a Comparative Review. Basic Clin. Pharmacol. Toxicol. 100, 4-22.
122. Spina, E.; Scordo, M. G. and D'Arrigo, C. (2003) Metabolic Drug Interactions With New Psychotropic Agents. Fundam. Clin. Pharmacol. 17, 517-538.
123. Steen, V. M.; Lovlie, R.; MacEwan, T. and McCreadie, R. G. (1997) Dopamine D3-Recptor Gene Variant and Susceptibility to Tardive Dyskinesia in Schizophrenic Patients. Mol. Psychiatry 2, 139-145.
124. Steimer, W.; Zöpf, K.; Von Amelunxen, S.; Pfeiffer, H.; Bachofer, J.; Popp, J.; Messner, B.; Kissling, W. and Leucht, S. (2004) Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers. Clin. Chem. 50, 1623-1633.
125. Steimer, W.; Zöpf, K.; Von Amelunxen, S.; Pfeiffer, H.; Bachofer, J.; Popp, J.; Messner, B.; Kissling, W. and Leucht, S. (2005) Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients With Low or High Risk for Side Effects in Amitriptyline Therapy. Clin. Chem. 51, 376-385.
126. Sullivan-Klose, T. H.; Ghanayem, B. I.; Bell, D. A.; Zhang, Z. Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J. O.; Birkett, D. J. and Goldstein, J. A. (1996) The Role of the CYP2C9-Leu359 Allelic Variant in the Tolbutamide Polymorphism. Pharmacogenetics 6, 341-349.
127. Suzuki, A.; Kondo, T.; Mihara, K.; Yasui-Furukori, N.; Ishida, M.; Furukori, H.; Kaneko, S.; Inoue, Y. and Otani, K. (2001) The -141C Ins/ Del Polymorphism in the Dopamine D2 Receptor Gene Promotor Region Is Associated With Anxiolytic and Antidepressive Effects During Treatment With Dopamine Antagonists in Schiphrenic Patients. Pharmacogenetics 11, 545-550.
128. Suzuki, Y.; Kawashima, Y.; Shioiri, T. and Someya, T. (2004) Effects of Concomitant Fluvoxamine on the Plasma Concentration of Etizolam in Japanese Psychiatric Patients: Wide Interindividual Variation in the Drug Interaction. Ther. Drug Monit. 26, 638-642.
129. Tan, E. C.; Chong, S. A.; Mahendran, R.; Dong, F. and Tan, C. H. (2001) Susceptibility to Neuroleptic-Induced Tardive Dyskinesia and the T102C Polymorphism in the Serotonin Type 2A Receptor. Biol. Psychiatry 50, 144-147.
130. Templeman, L. A.; Reynolds, G. P.; Arranz, B. and San, L. (2005) Polymorphisms of the 5-HT2C Receptor and Leptin Genes Are Associated With Antipsychotic Drug-Induced Weight Gain in Caucasian Subjects With a First-Episode Psychosis. Pharmacogenetics and Genomics 15, 195-200.
131. Theisen, F. M.; Hinney, A.; Bromel, T.; Heinzel-Gutenbrunner, M.; Martin, M.; Krieg, J. C.; Remschmidt, H. and Hebebrand, J. (2004) Lack of Association Between the -759C/T Polymorphism of the 5-HT2C Receptor Gene and Clozapine-Induced Weight Gain Among German Schizophrenic Individuals. Psychiatr. Genet. 14, 139-142.
132. Toscano, C.; Klein, K.; Blievernicht, J.; Schaeffeler, E.; Saussele, T.; Raimundo, S.; Eichelbaum, M.; Schwab, M. and Zanger, U. M. (2006) Impaired Expression of CYP2D6 in Intermediate Metabolizers Carrying the *41 Allele Caused by the Intronic SNP 2988G>A: Evidence for Modulation of Splicing Events. Pharmacogenetics and Genomics 16, 755-766.
133. Tucker, G. T.; Silas, J. H.; Iyun, A. O.; Lennard, M. S. and Smith, A. J. (1977) Polymorphic Hydroxylation of Debrisoquine in Man. Lancet 2, 718.
134. Tyndale, R.; Aoyama, T.; Broly, F.; Matsunaga, T.; Inaba, T.; Kalow, W.; Gelboin, H. V.; Meyer, U. A. and Gonzalez, F. J. (1991) Identification of a New Variant CYP2D6 Allele Lacking the Codon Encoding Lys-281: Possible Association With the Poor Metabolizer Phenotype. Pharmacogenetics 1, 26-32.
135. van der Weide, J. and Hinrichs, J. W. J. (2006) The Influence of Cytochrome P450 Pharmacogenetics on Disposition of Common Antidepressant and Antipsychotic Medications. Clin. Biochem. Rev. 27, 17-25.
136. van der Weide, J.; Steijns, L. S. W. and van Weelden, M. J. M. (2003) The Effect of Smoking and Cytochrome P450 CYP1A2 Genetic Polymorphism on Clozapine Clearance and Dose Requirement. Pharmacogenetics 13, 169-172.
137. van der Weide, J.; van Baalen-Benedek, E. H. and Kootstra-Ros, J. E. (2005) Metabolic Ratios of Psychotropics As Indication of Cytochrome P450 2D6/2C19 Genotype. Ther. Drug Monit. 27, 478-483.
138. van Marwijk, H. W.; Bijl, D.; Ader, H. J. and de Haan, M. (2001) Antidepressant Prescription for Depression in General Practice in The Netherlands. Pharm. World Sci. 23, 46-49.
139. Wang, Y. C.; Bai, Y. M.; Chen, J. Y.; Lin, C. C.; Lai, I. C. and Liou, Y. J. (2005) C825T Polymorphism in the Human G Protein Beta3 Subunit Gene Is Associated With Long-Term Clozapine Treatment-Induced Body Weight Change in the Chinise Population. Pharmacogenetics and Genomics 15, 743-748.
140. Yokota, H.; Tamura, S.; Furuya, H.; Watanabe, M.; Kanazawa, I.; Kondo, S. and Gonzalez, F. J. (1993) Evidence for a New Variant CYP2D6 Allele CYP2D6J in a Japanese Population Associated With Lower in Vivo Rates of Sparteine Metabolism. Pharmacogenetics 3, 256-263.
141. Yoshida, K.; Ito, K.; Sato, K.; Takahashi, H.; Kamata, M.; Higushi, H.; Shimizu, T.; Itoh, K.; Inoue, K.; Tezuka, T.; Suzuki, T.; Ohkubo, T.; Sugawara, K. and Otani, K. (2002) Influence of the Serotonin Transporter Gene-Linked Polymorphic Region on the Antidepressant Response to Fluvoxamine in Japanese Depressed Patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 383-386.
142. Zanardi, R.; Benedetti, F.; Di Bella, D.; Catalano, M. and Smeraldi, E. (2000) Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promotor of the Serotonin Transporter Gene. J. Clin. Psychopharmacol. 20, 105-107.
143. Zhang, Z. J.; Zhang, X. B.; Sha, W. W.; Zhang, X. B. and Reynolds, G. P. (2002) Association of a Polymorphism in the Promotor Region of Serotonin 5-HT2C Receptor Gene With Tardive Dyskinesia in Patients With Schizophrenia. Mol. Psychiatry 7, 670-671.